More than 800 new cases of breast cancer could be detected in Nova Scotia this year. It is the most common cancer in women. © JOEL SAGET/afp via getty images
The Canadian Cancer Society's latest report for 2024 highlights the ongoing prominence of prostate, breast, and lung cancers in Nova Scotia. Despite this consistency, advancements in research and management are shaping the approach to these diseases.
In Nova Scotia, the Canadian Cancer Society's projections underscore the continued prevalence of prostate, breast, and lung cancers. These malignancies remain the most frequently diagnosed cancers in the region. However, alongside the steadfast nature of these statistics, there is an evolution occurring in the understanding and handling of these conditions.
Bernard Petolas, a resident of Halifax and a prostate cancer survivor, exemplifies the changing landscape of cancer care. Diagnosed six years ago, Petolas has not only overcome his illness but also dedicates a portion of his time to the Prostate Cancer Patient Empowerment Program. This initiative, initiated in 2016 by a researcher from Dalhousie University, aims to address the often-overlooked mental health aspect of cancer care. Petolas notes the profound impact of psychological support on his journey to recovery, highlighting the program's holistic approach that incorporates physical and nutritional advice alongside emotional assistance.
Prostate cancer is particularly notable among men, being both the most common and one of the most treatable cancers. However, in Nova Scotia, it still accounts for a significant number of diagnoses and deaths. The province has taken proactive steps by launching a pilot screening program for lung cancer, another prevalent malignancy in the region. This initiative aims to streamline the screening process, allowing individuals at risk to bypass primary care and consult directly with specialized practitioners.
While the incidence rates of these common cancers show signs of improvement, there is a concerning trend emerging with less common cancers like kidney, liver, and skin cancers. David Raynaud, a principal advocate for public interest at the Canadian Cancer Society, warns of rising incidence rates for these lesser-known malignancies. Despite advancements in research and screening techniques, these cancers pose a growing threat, necessitating continued vigilance and investment.
The progress made in cancer research and prevention is evident, with improved screening tests facilitating earlier detection. However, the overall number of cancer diagnoses and deaths continues to rise, driven by population growth and aging demographics. This reality underscores the ongoing importance of research funding and collaborative efforts to combat cancer effectively.
Raynaud emphasizes the regional disparities in cancer outcomes, with eastern provinces experiencing higher mortality rates compared to their western counterparts. Lifestyle habits, prevention efforts, and demographic factors all contribute to this divide, highlighting the need for tailored interventions to address specific regional challenges.
In response to these trends, the Canadian Cancer Society calls on federal and provincial authorities to maintain their commitment to cancer research funding. Despite being the leading cause of death in the country, cancer research receives significant investment from the Society, reflecting its dedication to advancing scientific understanding and improving patient outcomes.
